AcesoStem Biostrategies Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $2.68M

  • Investors
  • 7

AcesoStem Biostrategies General Information

Description

Developer of drugs and therapeutics designed to provide treatment for rotator cuff disease. The company's therapeutics are used in osteoarthritis treatment, musculoskeletal disorders, and other regenerative technologies, enabling healthcare professionals to provide patients suffering from Orthopedic conditions with effective treatment and help them recover.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 813, Boramae-ro 5ga-gil 7
  • Gwanak-gu, Bongcheon-dong, Character Greenville
  • Seoul, 08708
  • South Korea
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 813, Boramae-ro 5ga-gil 7
  • Gwanak-gu, Bongcheon-dong, Character Greenville
  • Seoul, 08708
  • South Korea

AcesoStem Biostrategies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AcesoStem Biostrategies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 01-Jun-2026 $2.68M Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 31-Oct-2023 Completed Clinical Trials - General
2. Early Stage VC (Series A) 12-Oct-2022 $1.41M $1.41M Completed Clinical Trials - General
1. Seed Round 28-Oct-2021 Completed Startup
To view AcesoStem Biostrategies’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AcesoStem Biostrategies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AcesoStem Biostrategies Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Premier Partners PE/Buyout Minority
Tech Incubator Program for Startup Accelerator/Incubator
Dream CIS Corporation Minority
Tap Angel Partners Venture Capital Minority
BlissVine Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

AcesoStem Biostrategies FAQs

  • When was AcesoStem Biostrategies founded?

    AcesoStem Biostrategies was founded in 2019.

  • Where is AcesoStem Biostrategies headquartered?

    AcesoStem Biostrategies is headquartered in Seoul, South Korea.

  • What is the size of AcesoStem Biostrategies?

    AcesoStem Biostrategies has 13 total employees.

  • What industry is AcesoStem Biostrategies in?

    AcesoStem Biostrategies’s primary industry is Drug Discovery.

  • Is AcesoStem Biostrategies a private or public company?

    AcesoStem Biostrategies is a Private company.

  • What is AcesoStem Biostrategies’s current revenue?

    The current revenue for AcesoStem Biostrategies is .

  • How much funding has AcesoStem Biostrategies raised over time?

    AcesoStem Biostrategies has raised $4.1M.

  • Who are AcesoStem Biostrategies’s investors?

    Premier Partners, Tech Incubator Program for Startup, Dream CIS, Tap Angel Partners, and BlissVine Ventures are 5 of 7 investors who have invested in AcesoStem Biostrategies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process